190 related articles for article (PubMed ID: 19254917)
1. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion.
Whelan BR; Isenberg DA
Rheumatology (Oxford); 2009 May; 48(5):594-5. PubMed ID: 19254917
[No Abstract] [Full Text] [Related]
2. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.
Valiyil R; Casciola-Rosen L; Hong G; Mammen A; Christopher-Stine L
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy in necrotizing autoimmune myopathy associated with anti-SRP antibody: A clinical case review.
Nóvoa Medina FJ; Gutiérrez Martínez J; González González Y; Romero Díaz B; Machín García S; Rosas Romero A
Reumatol Clin (Engl Ed); 2018; 14(6):379-381. PubMed ID: 28389200
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases.
Frikha F; Rigolet A; Behin A; Fautrel B; Herson S; Benveniste O
Rheumatology (Oxford); 2009 Sep; 48(9):1166-8. PubMed ID: 19549788
[No Abstract] [Full Text] [Related]
5. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients.
Majmudar S; Hall HA; Zimmermann B
J Clin Rheumatol; 2009 Oct; 15(7):338-40. PubMed ID: 20009968
[TBL] [Abstract][Full Text] [Related]
6. Prospects for B-cell-targeted therapy in autoimmune disease.
Edwards JC; Cambridge G
Rheumatology (Oxford); 2005 Feb; 44(2):151-6. PubMed ID: 15509628
[No Abstract] [Full Text] [Related]
7. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases.
Cooper N; Arnold DM
Br J Haematol; 2010 Apr; 149(1):3-13. PubMed ID: 20151975
[TBL] [Abstract][Full Text] [Related]
8. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).
Arlet JB; Dimitri D; Pagnoux C; Boyer O; Maisonobe T; Authier FJ; Bloch-Queyrat C; Goulvestre C; Heshmati F; Atassi M; Guillevin L; Herson S; Benveniste O; Mouthon L
Neuromuscul Disord; 2006 May; 16(5):334-6. PubMed ID: 16616848
[TBL] [Abstract][Full Text] [Related]
9. B cell targeted therapy in autoimmunity.
Blank M; Shoenfeld Y
J Autoimmun; 2007; 28(2-3):62-8. PubMed ID: 17391915
[TBL] [Abstract][Full Text] [Related]
10. Anti-SRP auto-antibodies are not specific for myositis: Report of 8 cases.
Rodríguez-Muguruza S; Lozano-Ramos I; Coll-Canti J; Hernández-Gallego A; Ojanguren I; Martinez-Caceres E; Olive A
Joint Bone Spine; 2017 Jan; 84(1):103-105. PubMed ID: 27236258
[No Abstract] [Full Text] [Related]
11. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies.
Suzuki S; Satoh T; Sato S; Otomo M; Hirayama Y; Sato H; Kawai M; Ishihara T; Suzuki N; Kuwana M
Rheumatology (Oxford); 2008 Oct; 47(10):1539-42. PubMed ID: 18687709
[TBL] [Abstract][Full Text] [Related]
12. Treating human autoimmune disease by depleting B cells.
Looney RJ
Ann Rheum Dis; 2002 Oct; 61(10):863-6. PubMed ID: 12228152
[No Abstract] [Full Text] [Related]
13. Anti-synthetase syndrome associated with anti PL-12 and anti-Signal recognition particle antibodies and a necrotizing auto-immune myositis.
Malkan A; Cappelen-Smith C; Beran R; Griffith N; Toong C; Wang MX; Cordato D
J Clin Neurosci; 2015 Feb; 22(2):396-8. PubMed ID: 25150763
[TBL] [Abstract][Full Text] [Related]
14. Anti-signal recognition particle autoantibody ELISA validation and clinical associations.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2015 Jul; 54(7):1194-9. PubMed ID: 25524922
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.
Pinal-Fernandez I; Parks C; Werner JL; Albayda J; Paik J; Danoff SK; Casciola-Rosen L; Christopher-Stine L; Mammen AL
Arthritis Care Res (Hoboken); 2017 Feb; 69(2):263-270. PubMed ID: 27111848
[TBL] [Abstract][Full Text] [Related]
16. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
Guzman Moreno R
Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
[TBL] [Abstract][Full Text] [Related]
17. [Anti-signal recognition particle autoantibody positive myopathy].
Bodoki L; Vincze M; Hortobágyi T; Griger Z; Csonka T; Dankó K
Ideggyogy Sz; 2014 Sep; 67(9-10):347-53. PubMed ID: 25518264
[TBL] [Abstract][Full Text] [Related]
18. [Clinical features and therapeutic response of our anti-SRP positive patients with myositis].
Botos B; Nagy-Vincze M; Dankó K
Orv Hetil; 2017 Sep; 158(35):1382-1389. PubMed ID: 28847176
[TBL] [Abstract][Full Text] [Related]
19. Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab.
Luca NJ; Atkinson A; Hawkins C; Feldman BM
J Rheumatol; 2012 Jul; 39(7):1483-5. PubMed ID: 22753802
[No Abstract] [Full Text] [Related]
20. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
